TSZY(SZ:002872)2019-04-25 16:00Financial Performance - The company's operating revenue for Q1 2019 was ¥474,746,180.04, a decrease of 23.56% compared to ¥621,078,286.32 in the same period last year[7]. - Net profit attributable to shareholders was ¥10,430,895.96, down 84.25% from ¥66,221,503.20 year-on-year[7]. - Basic and diluted earnings per share were both ¥0.0328, reflecting an 84.25% decline from ¥0.2083 in the same period last year[7]. - Net profit for Q1 2019 was ¥11,069,406.43, a decline of 83.7% from ¥67,460,113.72 in Q1 2018[38]. - Comprehensive income for the quarter totaled ¥11,174,338.27, compared to ¥67,562,771.26 in the previous year[42]. - Operating revenue for the first quarter was ¥139,603,039.17, a decrease of 22.7% compared to ¥180,420,480.26 in the previous period[41]. Cash Flow - The net cash flow from operating activities increased by 299.52% to ¥51,010,099.91, compared to a negative cash flow of ¥25,566,537.71 in the previous year[7]. - Operating cash flow generated was ¥51,010,099.91, a significant improvement from a negative cash flow of -¥25,566,537.71 in the previous period[46]. - The net cash flow from operating activities for the first quarter was CNY 49,526,423, an increase of 24% compared to CNY 39,988,588 in the previous period[50]. - Total cash inflow from operating activities was CNY 243,510,035, while cash outflow was CNY 193,983,612, resulting in a net cash inflow of CNY 49,526,423[50]. - The total cash and cash equivalents at the end of the period was CNY 76,199,258, down from CNY 291,555,091 in the previous period[51]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,727,337,108.96, a slight decrease of 0.47% from ¥4,749,805,702.28 at the end of the previous year[7]. - Total current assets amounted to RMB 1,735,303,855.95, a decrease from RMB 1,759,411,560.31 at the end of 2018[28]. - Total liabilities decreased to RMB 1,458,331,882.97 from RMB 1,491,996,178.18 at the end of 2018[29]. - The total assets as of March 31, 2019, were RMB 4,727,337,108.96, slightly down from RMB 4,749,805,702.28 at the end of 2018[30]. - The company's total equity increased to RMB 3,269,005,225.99 from RMB 3,257,809,524.10 at the end of 2018[30]. Shareholder Information - The company reported a total of 36,649 common shareholders at the end of the reporting period[11]. - The company's net assets attributable to shareholders increased by 0.33% to ¥3,200,827,028.04 from ¥3,190,269,836.62 at the end of the previous year[7]. - The company's equity attributable to shareholders was CNY 3,190,269,836, reflecting a strong capital position[55]. Expenses - Total operating costs for Q1 2019 were ¥461,609,196.04, down 18.5% from ¥565,781,145.90 in the previous year[36]. - The company reported a decrease in research and development expenses to ¥5,615,898.02, down 28.0% from ¥7,794,987.95[36]. - Research and development expenses were ¥2,248,879.98, down 52.0% from ¥4,676,568.69 in the previous year[41]. - The significant increase in sales expenses was attributed to the implementation of the two-invoice system, leading to higher costs[15]. - Sales expenses increased to ¥11,810,939.64, compared to ¥1,098,867.43 in the previous period, indicating a rise in marketing efforts[41]. Regulatory and Compliance - The subsidiary Hunan Tiansheng Pharmaceutical Co., Ltd. received the drug registration approval for injectable flucloxacillin sodium (0.5g, 1.0g) from the National Medical Products Administration[16]. - The company obtained the Drug GMP Certificate from the Chongqing Drug Administration, renewing the previous certification[16]. - The company reported no violations regarding external guarantees during the reporting period[20]. - The first quarter report was not audited, indicating a potential area for further scrutiny[59]. Government Support - The company received government subsidies amounting to ¥2,635,375.66, which was significantly lower than the previous year's amount[8].